6-Aminoquinolones as new potential anti-HIV agents

Article abstract of DOI:10.1021/jm9903390

A series of 6-aminoquinolone compounds were evaluated for their in vitro activity against human immunodeficiency virus type 1 (HIV-1). Compound 12a, bearing a methyl substituent at the N-1 position and a 4-(2-pyridyl)-1-piperazine moiety at the C-7 positi

Full text of DOI:10.1021/jm9903390

J . Med. Chem. 2000, 43, 3799-3802
3799
6-Am in oqu in olon es a s New P oten tia l An ti-HIV Agen ts
Violetta Cecchetti,‡ Cristina Parolin,† Stefano Moro,§ Teresa Pecere,† Enrica Filipponi,‡ Arianna Calistri,†
Oriana Tabarrini,‡ Barbara Gatto,§ Manlio Palumbo,*,§ Arnaldo Fravolini,‡ and Giorgio Palu' †
Dipartimento di Chimica e Tecnologia del Farmaco, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy, Institute of
Microbiology, University of Padova, Via A. Gabelli 63, 35131 Padova, Italy, and Department of Pharmaceutical Sciences,
University of Padova, Via Marzolo 5, 35131 Padova, Italy
Received J uly 1, 1999
A series of 6-aminoquinolone compounds were evaluated for their in vitro activity against human
immunodeficiency virus type 1 (HIV-1). Compound 12a , bearing a methyl substituent at the
N-1 position and a 4-(2-pyridyl)-1-piperazine moiety at the C-7 position, was the most active
in inhibiting HIV-1 replication on de novo infected C8166 human lymphoblastoid cell lines.
The 12a EC50 value was 0.1 µM, a 7-20-fold lower concentration relative to that for compounds
8a and 7a containing a cyclopropyl and tert-butyl substituent at the N-1 position, respectively.
When the C-6 amino group was replaced with a fluorine atom, a decreased antiviral effect was
observed. The observed effects are selective, since potency is substantially reduced when testing
the compounds against the herpes simplex virus type 1 (HSV-1). Active quinolone derivatives
very efficiently interact with TAR RNA, which suggests a nucleic acid-targeted mechanism of
action.
In tr od u ction
ethyl R-aroyl-â-(dimethylamino)acrylate derivatives by
sequential reaction with appropriate amines and cy-
clization, the desired N-substituted ethyl 7-chloro-6-
nitro(or fluoro)-4-oxo-1,4-dihydroquinoline-3-carboxylate
intermediates were obtained. The synthons, ethyl 7-
chloro-1-tert-butyl(or cyclopropyl)-6-nitro-4-oxo-1,4-di-
hydroquinoline-3-carboxylates, were elaborated to the
6-amino-1-tert-butyl and 6-amino-1-cyclopropyl target
acids 7a -f and 8a respectively, as well as ethyl 7-fluoro-
1,8-dimethyl-6-nitro-4-oxo-1,4-dihydroquinoline-3-car-
boxylate to the 6-amino-1,8-dimethyl acid 16a , through
a three-step sequence: nucleophilic displacement of the
C-7 halogen with appropriate heterocyclic bases, cata-
lytic reduction of the C-6 nitro group, and basic or acidic
hydrolysis.
The search for new anti-HIV compounds continues to
be a major challenge in antiviral chemotherapy. Despite
the recent success of highly active antiretroviral therapy
(HAART) in prolonging survival of AIDS patients and
in reducing morbidity due to opportunistic infections,1
long-term toxicity of combinations of antireverse tran-
scriptase and antiprotease drugs and selection of drug-
resistant viral mutants are still a major concern. Efforts
are therefore devoted to the discovery of compounds
with diverse mechanisms of action.
It has been recently found that antibacterial fluoro-
quinolones can exhibit antiviral activity per se. Two
analogues,2-4 bearing a 3,4-didehydro-4-phenyl-1-pip-
eridinyl moiety at the C-7 position, exhibited EC50
<
Similarly, 6-amino-1-methyl acid 12a was obtained
from ethyl 7-chloro-1-methyl-6-nitro-4-oxo-1,4-dihydro-
quinoline-3-carboxylate via intermediate 10a (ethyl
1-methyl-6-nitro-7-[4-(2-pyridyl)-1-piperazinyl]-4-oxo-
1,4-dihydroquinoline-3-carboxylate) and its reduced
6-amino analogue 11a . The intermediate 10a was
exploited to obtain amide derivative 13a ; thus, it was
hydrolyzed to the corresponding nitro acid, which was
coupled with 1-(2-pyridyl)piperazine utilizing 1,1′-car-
bonyldiimidazole (CDI) and then reduced. On the other
hand, intermediate 11a was elaborated into 6-methyl-
amino derivative 14a via the trifluoroacetamide deriva-
tive.
50 nM in chronically infected cells. They were suggested
to act, at least in part, through inhibition of cellular
factors working or cooperating with Tat.4
Preliminary tests suggest that also the new family of
6-aminoquinolones, originally synthesized as potential
antibacterials,5 could exhibit anti-HIV and anti-HSV
activities, a possible lead being represented by the 1-tert-
butyl-7-[4-(2-pyridyl)-1-piperazinyl] derivative 7a .6 We
report here the synthesis and antiviral activities of
additional 6-aminoquinolones (7c-f, 8a , 9, 12a -14a ,
and 16a ) and a preliminary characterization on their
mechanism of action. Several comparative 6-fluoro
analogues (20a -22a ) were also prepared and tested.
The target acid derivative 9, bearing a 4-(2-pyridyl)-
1-piperazinyl at the N-1 position, was obtained from
7-chloro-1-[4-(2-pyridyl)-1-piperazinyl]-6-nitro-4-oxo-1,4-
dihydroquinoline-3-carboxylate by catalytic reduction
and subsequent acid hydrolysis. Finally, the C-6 fluoro
acid derivatives 20a -22a were prepared from the
corresponding ethyl 7-chloro-1-tert-butyl(or cyclopropyl
or methyl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-car-
boxylate, respectively, through nucleophilic and acidic
hydrolysis steps.
Ch em istr y
The cycloaracylation procedure was employed to build
the quinolone framework. Thus, starting with suitable
* To whom correspondence should be addressed. Tel:
+39 049 827 5711. Fax: +39 049 827 5366. E-mail: mpalumbo@
purple.dsfarm.unipd.it.
‡ Dipartimento di Chimica e Tecnologia del Farmaco.
† Institute of Microbiology.
§ Department of Pharmaceutical Sciences.
10.1021/jm9903390 CCC: $19.00 © 2000 American Chemical Society
Published on Web 09/19/2000

3800 J ournal of Medicinal Chemistry, 2000, Vol. 43, No. 20
Brief Articles
Biologica l Eva lu a tion
We have identified three important features that
contribute to the enhancement of antiviral activity: (a)
the presence of the carboxylic acid at the C-3 position;
(b) the presence of a small polar group at the C-6
position and bulky substituents at the C-7 position, and
(c) the presence of small substituents at the N-1 position
of the quinolone moiety. As experimentally demon-
strated, there are some structural limitations at the N-1
and C-8 positions: bulky substituents are not well
tolerated at either N-1 and/or C-8, whereas no steric
restrictions are present around the C-7 position. RNA-
binding data confirm that the carboxylic function of
quinolones has to be free for efficient interaction. In
addition, to ensure a specific contact to TAR, appropri-
ate substituents must be located at positions 6 and 7 of
the quinolone moiety, as indicated by the lack of
response exhibited by 11a and ciprofloxacin. It is worth
observing that the latter two compounds are very poorly
active as anti-HIV-1 agents (Table 1), which supports
the hypothesis that RNA-quinolone interaction is
relevant to antiviral activity. Indeed, improved affinity
for the target seems to represent the basis for the
improved selectivity profile observed for 12a . In keeping
with this, preliminary data suggest that compounds
having a poorer SI (and activity), like 7a , also exhibit
reduced binding.
Since active 6-aminoquinolones are cytotoxic and
since the highest selectivity index obtained is 85, one
could assume that this class of molecules perturbs
physiological cellular functions or signals acting through
a nucleic acid intermediate as well. To address the issue
of antiviral versus cytotoxic activity, it will be now
crucial to further elucidate the mechanism of action of
the new quinolones at the molecular and biochemical
levels. In particular, the interactions of 6-aminoquino-
lones with other genomic viral sequences should be
investigated to assess their interference with the main
events of HIV-1 replication.
An tivir a l Activity. Anti-HIV-1 activity and toxicity
data, reported in Table 1, show that the most potent
drug is 7-[4-(2-pyridyl)-1-piperazinyl] derivative 12a ,
which bears a methyl group at the N-1 position. It
exhibits an EC50 in the submicromolar range, followed
by compounds 8a and 7a containing a tert-butyl and
cyclopropyl at the N-1 position, respectively. The corres-
ponding 6-fluoro congeners were 5-10-fold less potent
(compare 7a , 8a , and 12a vs 20a , 21a , and 22a ,
respectively). However, the N-1 substituent effect on
their relative activity was in the same order as that
found for 6-aminoquinolones: 22a (methyl) > 21a (cyclo-
propyl) > 20a (tert-butyl).
Alkylation of the C-6 amino group, as in the 6-meth-
ylamino derivative 14a , drastically decreased antiviral
response, pointing to the importance of an unsubstituted
amine at C-6. Comparison of compounds 12a and 16a
shows that the C-8 substituent is also crucial in terms
of interaction with the molecular target. Esterification
of the carboxyl group at the C-3 position dramatically
reduced antiviral activity and cytotoxic potential, thus
confirming the key role generally played by this portion
of the molecule in the biological activity of quinolones.
The test compounds appear to be selective for HIV,
since they were substantially less potent (the TC50
increases by almost 2 orders of magnitude) against an
HSV-1 wild-type strain, not withstanding their low level
of toxicity for Vero cells (Table 1).
In ter a ction w ith Vir a l Nu cleic Acid Sequ en ces.
Fluorometric titration experiments were carried out
with compounds 11a , 12a , and ciprofloxacin in the
presence of RNA and DNA sequences. The key results
are reported in Figure 1. Clearly, addition of TAR RNA
largely reduces the fluorescence quantum yield of 12a
(panel A), indicating the formation of a stable complex.
Conversely, derivative 11a was practically unaffected
by addition of the viral nucleic acid (panel B). The same
was true for a classical fluoroquinolone like ciprofloxacin
(not shown). Control experiments showed much lower
changes in fluorescence emission of 12a in the presence
of a TAR-unrelated t-RNA sequence or calf thymus
DNA, for both of which a slight increase, rather than a
decrease, in fluorescence emission is observed, even in
the presence of a 1000-fold excess of the nucleic acid
(panel C). Hence, specific recognition of the viral ribo-
nucleic acid depends on the structure of the test qui-
nolone and reflects HIV-1 inhibition properties. In
addition, complex formation between TAR and 12a is
quite effective, since we observed saturation of fluores-
cence emission at a nucleic acid concentration in the
submicromolar range.
Exp er im en ta l Section
An tivir a l a n d Cytotoxicity Assa ys. All compounds were
dissolved in dimethyl sulfoxide at 25 mM or higher concentra-
tion to exclude any cytotoxic effect of dimethyl sulfoxide after
dilution in the appropriate media. The anti-HIV-1 activities
and toxicities of compounds were assessed in C8166 with HIV-
1IIIB as described before.7 The anti-HSV-1 activity was
assayed in Vero cells by a plaque reduction method as
previously described.7 The inhibitory activity against HIV-1
was determined by examining cell cultures for syncytium
formation and by measuring reverse trancriptase (RT) activity
of culture supernatants.8 The antiviral activity was also
evaluated by measuring antigen gp120 production with an
ELISA method and by using a cytopathic effect reduction assay
as reported by Weinslow et al.9 The results shown in Table 1
represent the mean of at least three different experiments
performed in triplicate.
Nu cleic Acid s: TAR RNA. T7 polymerase was used for in
vitro transcription of pGEM7 zf(+) containing HIV-1 sequences
(HXBc2 strain) from nucleotide +454 to nucleotide +558,
where +1 represents the first nucleotide of the 5′-LTR.10 RNA
was precipitated by adding 1/10 volume of 3 M sodium acetate
and 2 volumes of ethanol at 0 °C.
t-RNA (from Wheat germ) and highly polymerized calf-
thymus DNA were purchased from Sigma Chemical Co. and
used following phenol extraction.
Discu ssion a n d Con clu sion s
The data presented here show that 6-aminoquinolones
represent useful novel leads for the development of new
and effective drugs for AIDS treatment. Indeed, 6-amino
derivatives appear to be more potent than the corres-
ponding fluorinated analogues as anti-HIV-1 agents.
Quite remarkably, 12a is the most potent compound of
the quinolone structural class so far described and also
the one with the most favorable selectivity index in
C8166 cells.
Sp ectr oscop ic Titr a tion s w ith RNA a n d DNA. Fluoro-
metric titrations were performed exploiting the drugs high
fluorescence yield upon excitation at 350 nm. Fluorescence

Brief Articles
J ournal of Medicinal Chemistry, 2000, Vol. 43, No. 20 3801
Ta ble 1. Structural, Anti-HIV-1, and Anti-HSV-1 Properties of the Tested 6-Aminoquinolones
a
b
Antiviral activity against human immunodeficiency virus type 1 in C8166 cells. EC50 represents the concentration of drug (µM)
which reduced reverse trancriptase (RT) activity of C8166 culture supernatants by 50%. c TC50 represents the concentration of drug (µM)
which reduced cell growth by 50%. SI represents the selectivity index (ratio of TC50 to EC50). e Antiviral activity against herpes simplex
d
virus type 1 in Vero cells. f Not tested due to its low solubility. CPX ) ciprofloxacin. RFX ) rufloxacin.
g
h

3802 J ournal of Medicinal Chemistry, 2000, Vol. 43, No. 20
Brief Articles
eliminate any particulate material that would interfere with
the fluorescence response.
Ack n ow led gm en t. We acknowledge financial sup-
port through AIDS Grant No. 407-76002 to G.P., MURST
Grants 60% and 40% to G.P. and M.P., Grant No. 770/
97 from Regione Veneto to M.P., and a grant from the
University of Perugia to A.F.
Su p p or tin g In for m a tion Ava ila ble: Reaction schemes
and detailed information on the synthesis and characterization
of individual compounds. This material is available free of
charge via the Internet at http://pubs.acs.org.
Refer en ces
(1) Palella, F.; Delaney, K.; Moorman, A.; Loveless, M.; Fuhrer, J .;
Satten, G.; Aschman, D.; Holmberg, S.; Investigators, T. H. O.
S. Declining Morbidity and Mortality among Patients with
Advanced Human Immunodeficiency Virus Infection. N. Engl.
J . Med. 1998, 338, 853-860.
(2) Baba, M.; Okamoto, M.; Makino, M.; Kimura, Y.; Ikeuchi, T.;
Sakaguchi, T.; Okamoto, T. Potent and selective inhibition of
Human Immunodeficiency Virus Type 1 transcription by pip-
erazinyloxoquinoline derivatives. Antimicrob. Agents Chemother.
1997, 41, 1250-1255.
(3) Witvrouv, M.; Daelemans, D.; Pannecouque, C.; Neyts, J .;
Andrei, G.; Snoeck, R.; Vandamme, A.; Balzarini, J .; Desmyter,
J .; Baba, M.; De Clercq, E. Broad-Spectrum Antiviral Activity
and Mechanism of Antiviral Action of Fluoroquinolone Deriva-
tive K-12. Antiviral Chem. Chemother. 1998, 5, 403-411.
(4) Baba, M.; Okamoto, M.; Kawamura, M.; Makino, M.; Higashida,
M.; Takashi, T.; Kimura, Y.; Ikeuchi, T.; Tetsuka, T.; Okamoto,
T. Inhibition of Human Immunodeficiency Virus Type 1 replica-
tion and cytokine production by fluoroquinoline derivatives. Mol.
Pharmacol. 1998, 53, 1097-1103.
(5) (a) Cecchetti, V.; Clementi, S.; Cruciani, G.; Fravolini, A.;
Pagella, P.; Savino, A.; Tabarrini, O. 6-Aminoquinolones: A New
Class of Quinolones Antibacterials? J . Med. Chem. 1995, 38,
973-982. (b) Cecchetti, V.; Fravolini, A.; Lorenzini, M. C.;
Tabarrini, O.; Terni, P.; Xin, T. Studies on 6-aminoquinolones:
Synthesis and antibacterial evaluation of 6-amino-8-methylqui-
nolones. J . Med. Chem. 1996, 39, 436-445.
(6) Cruciani, G.; Fravolini, A.; Cecchetti, V.; Filipponi, E.; Tabarrini,
O.; Palu′, G.; Del Pup, L.; Parolin, C. Quinolones as anti-HIV-1
agents. Atti XII Conv. Naz. Div. Chim. Farm. Abstr. C-M5 1996,
71.
F igu r e 1. Aminoquinolone 12a exhibits high-affinity binding
to TAR RNA. Panel A: Changes in emission spectrum of 12a
(2 µM, spectrum 1) upon addition of increasing amounts of
TAR RNA up to 0.2 µM (spectrum 2). Panel B: Same
measurements for 11a (6 µM, spectrum 1) up to 0.2 µM TAR
RNA (spectrum 2). Panel C: Changes in emission spectrum
of 12a (1 µM, spectrum 1) upon addition of large excess (1 mM)
of calf thymus DNA (spectrum 2). Excitation wavelength was
350 nm, and every spectrum was recorded at 25 °C after
allowing 5 min of equilibration in 10 mM Tris, pH 7.0, 20 mM
NaCl, and 1 mM Mg(ClO4)2.
(7) (a) Mahmood, N.; Moore, P.; De Tommasi, N.; De Simone, F.;
Colman, S.; Hay, A.; Pizza, C. Inhibition of HIV-1 Infection by
Caffeoylquinic Derivatives. Antiviral Chem. Chemother. 1993,
4, 235-240. (b) Palu`, G.; Palumbo, M.; Cusinato, R.; Meloni, G.
A.; Marciani-Magno, S. Antiviral properties of psoralen deriva-
tives: a biological and physicochemical investigation. Biochem.
Pharmacol. 1984, 33, 3451-3456.
(8) Rho, H.; Poiesz, B.; Ruscetti, F.; Gallo, R. Characterization of
the Reverse Transcriptase from
a New Retrovirus (HTLV)
Produced by a Human Cutaneous T-Cell Lymphoma Cell Line.
Virology 1981, 112, 355-360.
(9) Weinslow, O.; Kiser, R.; Fine, D.; Bader, J .; Shoemaker, R.; Boyd,
M. New Soluble Formazan Assay for HIV-1 Cytopathic Effects:
Application to High-Flux Screening of Synthetic and Natural
Products for AIDS-Antiviral Activity. J . Natl. Cancer Inst. 1989,
81, 577-586.
spectra were recorded at 25 °C on a luminescence spectropho-
tometer LS50B (Perkin-Elmer). Titrations were performed in
Tris HCl (10 mM, pH 7.0), NaCl (20 mM) and Mg(ClO4)2 (1
mM) by adding increasing amounts of concentrated nucleic
acid to diluted quinolones solutions and recording the emission
spectra 5 min after mixing to ensure equilibrium. Quinolone
concentration was evaluated by absorption spectroscopy. Each
solution was filtered through a 5-µm filter before use to
(10) Fisher, R.; Collati, E.; Ratner, L.; Gallo, R.; Wong-Staal, F. A
molecular clone of HTLV-III with biological activity. Nature
1985, 316, 262-265.
J M9903390